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Abstract 
Purpose: To examine the ethnomedicinal claims regarding the antidiabetic uses of Cassia sophera L. 
(Caesalpiniaceae) using an alloxan-induced diabetes model.  
Methods: The methanol extracts of leaves (CSLM) and roots (CSRM) of C. sophera were evaluated for 
hypoglycemic and anti-diabetic activities in normal and alloxan-induced diabetic rats. Alloxan (120 
mg/kg, i.p.) was administered to induce diabetes in rats. A dose regime of 50, 100 and 200 mg/kg of 
CSLM and CSRM was given orally to the respective groups (n = 6). Blank group consisted of normal 
animals maintained on saline. The diabetic untreated group served as negative control while the group 
that received glibenclamide (5 mg/kg) was positive control.  
Results: A significant (p < 0.05) lowering of fasting blood glucose level FBG in oral glucose tolerance 
test (OGTT) in normal rats was observed after daily administration of the extract for 7 days. Both 
extracts demonstrated decreased (p < 0.05) BGL with significantly (p < 0.05) improved glucose 
tolerance and body weight at the end of 4th, 7th and 14th day in extract-treated diabetic rats when 
compared with negative control and normal untreated group, respectively. In normoglycemic rats, CSLM 
and CSRM showed dose-dependent decrease in BGL. 
Conclusion: These results suggest that both extracts possess significant blood glucose lowering 
activity in normal as well as in diabetic rats.   
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Diabetes mellitus, at present, affects 
approximately 220 million people worldwide and 
this number is highly expected to increase in 
double proportions by 2030. At present, diabetes 
mellitus and its associated complications are 
reported to cause the death of six people every 
minute [1].  Impaired glucose tolerance 
(postprandial and fasting hyperglycemia) and 
variations in lipid and protein metabolism 
associated with absolute or relative insulin 
resistance and pancreatic β-cell dysfunction are 
typical features of Type 2 diabetes. Therefore, 
haemostatic balance of glucose is needed to 
minimize the complications associated with the 
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Increased insulin secretion by β-cells, enhanced 
sensitivity of organs to insulin and reduced 
postprandial glucose absorption are the 
exemplary approaches, which are in practice to 
deal with risk factors of diabetes mellitus [3]. 
However, clinically used anti-diabetic agents 
such as glibenclamide produce serious side 
effects (cholestatic jaundice, anemias, renal 
failure etc.)[4]. Therefore, effective and safer 
anti-diabetic agents that can cope with 
complications associated with diabetes mellitus 
are still needed [5]. Plants offer an easily 
accessible and cost-effective source for the 
discovery of such therapeutic agents with lesser 
side effects [6]. 
 
Cassia sophera L. (Family Caesalpiniaceae) is 
an annual shrub found throughout tropical and 
sub-tropical regions in Pakistan, India and China. 
It is 1 - 3 m tall with compound leaves consisting 
of 4 - 12 pairs of leaflets. The ethnomedicinal 
reputation of this plant includes its use in 
treatment of diabetes, rheumatic disorders, 
constipation, bronchitis, asthma and liver 
diseases [7]. It is considered to possess 
anticancer and anti-inflammatory properties. 
Flavonoids, anthraquinones, saponins, sterols, 
tannins and terpenoids have been isolated from 
root, stem bark and whole plant ethanol extracts 
of C. sophera [5,8]. The aim of the present study 
was to evaluate the anti-diabetic activities of the 
leaf and root extracts of C. sophera in order to 






The plant material was collected from Sargodha 
District, Pakistan in December 2012 and 
authenticated by Prof Dr Altaf Ahmad Dasti, 
Director, Institute of Pure and Applied Biology, 
Bahauddin Zakariya University, Multan, Pakistan. 
A specimen bearing voucher no. SWT-366 was 
preserved in the herbarium of the institution. The 
plant material was air-dried under shade for 15 
days at room temperature. The dried plant 
material was powdered using grinder and stored 





The maceration of powdered leaves and roots 
(500 g each) was done in methanol for a period 
of 24 h separately and then filtered. The 
procedure was repeated thrice using 1.0 L 
methanol in each step. The filtrates from each 
step were combined and concentrated using 
rotavapor (Buschi, Switzerland) at 35 °C.  The 
roots yielded crude methanol extract 25.3 g (5.06 
% of dry weight). While the yield of leaf methanol 




Adult Wistar rats with body weight range of 180 – 
220 g were used in the experiments. The animals 
were kept in the animal house of Department of 
Pharmacy, Bahauddin Zakariya Unversity, 
Multan, Pakistan. A standard room temperature 
of 25 ± 1 °C; relative humidity of 45 – 55% and a 
12 h light/dark cycle for 7 days with free access 
to food and water ad libitum under hygienic 
conditions were maintained. Before start of 
experiments, animals were acclimatized to 
laboratory conditions for 48 h. The Institutional 
Animal Ethical Committee of Department of 
Pharmacy, B. Z. U. Multan granted approval for 
the animal experiments (no. 
IAEC/Approval/01/2014/Pharm) as per OECD 
guidelines 2006 [9] 
 
Assessment of hypoglycaemic activity in 
normal rats  
 
Animals were divided into eight groups (n = 6). 
Groups 1 received distilled water. Groups 2, 3 
and 4 received CSLM at doses of 50, 100 and 
200 mg/kg, p.o. daily. Groups 5, 6 and 7 were 
administered 50, 100 and 200 mg/kg doses of 
CSRM orally. Group 8 received Glibenclamide (5 
mg/kg, p.o.) as a standard drug. Treatment was 
done daily for 7 days. Animals in all the groups 
received glucose (2 g/kg, p.o.), 30 min after the 
extract or standard drug administration in order 
to estimate oral glucose tolerance. Blood 
samples were collected from the tail vein prior to 
(0 h) and at 1, 2, 4 h after glucose  administration 
on the 0 day and on the 4th and 7th days after 16 
h of overnight fasting for glucose level estimation 
during 7 days of treatment period [1]. 
 
Assessments of anti-diabetic activity in 
alloxan-induced diabetic rats  
 
A fresh solution of alloxan monohydrate was 
prepared and subsequently administered to rats 
at a dose of 120 mg/kg body wt. In order to 
prevent hypoglycaemia following alloxan 
injection, the rats were maintained on a glucose 
solution (5 % w/v) for next 24 h. The rats 
showing persistent hyperglycaemia for next 7 
days within the range of 290 to 400 mg/dL 
(fasting blood glucose level) were selected. Such 
animals were divided into nine groups namely 
Group 1 (Normal untreated), Group 2 (Diabetic 
untreated), Group 3 (CSLM 50 mg/kg, p.o.), 
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Group 4 (CSLM 100 mg/kg, p.o.), Group 5 
(CSLM 200 mg/kg, p.o.), Group 6 (CSRM 50 
mg/kg, p.o.), Group 7 (CSRM 100 mg/kg, p.o.), 
Group 8 (CSRM extract 200 mg/kg, p.o.) and 
Group 9 (Glibenclamide 5 mg/kg, p.o.). 
 
Following administration of extracts/ 
glibenclamide daily for 14 days to the respective 
groups, blood samples were collected by retro-
orbital puncture at 0, 1, 2, and 4 h on the 4th, 7th 
and 14th day for estimation of blood glucose 
level. Oral glucose tolerance test (OGTT) was 
performed on day 14 by orally administering 
glucose at a dose of 2 g/kg b.w. 30 minutes after 
the administration of extracts/glineclamide. 
Measurement of body weights was also carried 
out on the 0, 4th, 7th, and 14th day an hour 
following treatment with the extracts/ 
glibenclamide in order to calculate percentage 




The data are expressed as mean ± SEM and 
were analyzed using one-way ANOVA followed 
by post hoc Duncan’s multiple range tests using 
SPSS software, version 15 (SPSS Inc, Chicago, 
IL, USA). P < 0.05 was considered statistically 





The methanol extract of roots (CSRM) and 
leaves (CSLM) significantly (p < 0.05) decreased 
fasting blood glucose level (FBG) in normal rats 
at 1, 2 and 4 h after treatment with 100 and 200 
mg/Kg of each extract. The dose of 200 mg/kg 
caused greater reduction as compared to that of 
100 mg/kg dose. However, 50 mg/kg of each 
extract failed to produce hypoglycemia. This 
leads to an assumption that the extracts caused 
hypoglycemia in normal rats more or less in a 
dose dependent manner. The hypoglycemic 
effect was more pronounced with CSRM after 
single dose administration. Repeated dose 
administration of CSRM and CSLM produced a 
significant (p < 0.05) reduction of FBG on 4th, 7th 
and 14th day with all doses, indicating that  both 
extracts can produce significant hypoglycemia on 
repeated administration. Both extracts at higher 
dose level i.e. 200 mg/kg, significantly (p < 0.05) 
reduced FBG level after single and repeated 
dose administration which is comparable with the 
FBG reduction produced by the positive control, 
glibenclamide (5 mg/kg) (Table 1). 
 
The effects of CSRM and CSLM on blood 
glucose level of glucose loaded rats in oral 
glucose tolerance test after 7 days pretreatment 
with test extracts was also studied. The blood 
glucose level (BGL) of rats pretreated for 7 days 
was significantly (p<0.05) reduced with CSRM 
and CSLM at 1 and 2 h at all doses as compared 
with normal control. Glibenclamide (5 mg/kg) 
significantly (p < 0.05) suppressed the BGL rise 
at all sampling intervals (Table 2). 
 
The significant (p < 0.05) reduction of the 
elevated BGL was observed on repeated 
administration of the CSLM and CSRM in 
normoglycemic rats when compared with the 
control groups. The results of the oral glucose 
tolerance test showed that both extracts 
produced significant (p < 0.05) reduction of the 
blood glucose levels at all dose levels on 1 and 2 
h intervals in normoglycemic rat. Intravenous 
injection of alloxan (120 mg/kg) resulted in raised 
BGL in rats with a range of 290-310 mg/dL after 
5 days. A significant reduction (p<0.05) in BGL 
was observed following single dose 
administration of CSRM and CSLM (100 and 200 
mg/kg) at 1, 2 and 4 h. However, Glibenclamide 
caused pronounced reduction in BGL at 1 and 2 
h after single dose in alloxan-induced diabetic 
rats. Repetition of dose regimen with CSRM and 
CSLM (50, 100 and 200 mg/kg) resulted in 
significant (p<0.05) and progressive decrease in 
the BGL over a period of two weeks. 
 




Blood glucose level (mg/dL) 
 0 h 1 h 2 h 4 h 4th day 7th day 14th day 
Normal 
untreated 
- 99.38±2.1 98.84±1.2 99.27±1.88 98.81±2.1 99.16±1.96 98.52±2.17 98.82±1.8 
CSLM 50 98.99±1.98 98.31±2.01 98.12±1.93 97.93±2.34 93.87±1.98* 89.31±2.62* 84.99±1.81* 
CSLM 100 99.45±1.83 95.31±2.34* 92.98±1.83* 86.3±1.79* 80.57±2.04* 74.34±3.2* 69.89±2.89* 
CSLM 200 98.87±1.9 93.11±1.68* 90.47±2.27* 83.05±1.94* 74.69±1.79* 68.34±2.7* 64.29±1.29* 
CSRM 50 97.94±2.7 97.31±1.82 97.13±1.89 96.73±2.04 92.45±2.11* 87.93±1.89* 81.16±2.89* 
CSRM 100 99.19±2.19 94.83±2.19* 90.65±2.07* 83.83±1.93* 78.87±1.98* 72.34±2.19* 68.79±1.95* 
CSRM 200 98.59±1.93 92.61±2.85* 89.33±1.88* 77.09±1.82* 69.3±2.13* 63.47±2.13* 59.38±2.09* 
Glibenclamide 5 99.69±2.08 91.86±1.64* 85.53±1.58* 73.89±1.67* 64.08±2.3* 58.39±1.62* 53.23±2.38* 
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Blood glucose level (mg/dl) 
0 h 1 h 2 h 4 h 
Normal 
untreated 
- 99.88±2.4 149.88±4.21 124.34±2.67 102.94±2.45 
CSLM 50 88.39±1.92 136.54±2.34* 114.54±2.03* 103.07±2.21 
CSLM 100  74.67±3.45 121.56±2.07* 101.59±1.92* 97.16±1.45 
CSLM 200 67.53±2.3 116.39±2.48* 92.24±2.72* 95.2±1.96 
CSRM 50 86.34±1.87 132.97±2.5* 109.92±3.15* 103.47±2.6 
CSRM 100 71.19±2.21 116.91±3.21* 99.5±2.37* 95.81±1.59 
CSRM 200 63.56±1.95 110.09±1.89* 88.53±2.63* 91.97±2.19* 
Glibenclamide 5 58.48±1.59 106.96±2.61* 83.15±1.98* 87.27±1.9* 
Data are expressed as mean ± SEM (n = 6); * p < 0.05 versus the normal untreated control group 
 
Animals treated with the methanol extract of 
roots and leaves at 100 and 200 mg/kg exhibited 
significant decrease (p < 0.05) in BGL on 4th, 7th 
and 14th day of treatment when compared to 
other groups of animals. The 50 mg/kg dose for 
each extract showed significant reduction (p < 
0.05) of BGL on 7th day and onwards. The results 
showed that CSRM was more potent compared 
to CSLM as it caused more reduction of BGL in 
diabetic animals. The results revealed the 
significant anti-hyperglycemic activity of C. 
sophera in alloxan-induced diabetic rats (Table 
3). 
 
Effects of methanol extracts of leaves and roots 
of C. sophera on blood glucose level of glucose 
loaded diabetic rats in oral glucose tolerance test 
on 14th day following treatment with test extracts 
were studied. Oral treatment with the CSRM and 
CSLM at all dose levels for 2 weeks had 
exhibited significantly improved results in OGTT 
as compared to diabetic untreated group (Table 
4). Alloxan (120 mg/kg, i.v.) had resulted in 
significant reduction (p < 0.05) of the body weight 
at the end of 7th and 14th day as compared to 
normal untreated group. Repeated dose 
treatment with Glibenclamide (5 mg/kg) caused 
prevention of body weight loss on 4th, 7th and 14th 
day in alloxan-induced diabetic rats. 
 




Blood glucose level (mg/dL) 
0 h 1 h 2 h 4 h 4th day 7th day 14th day 
Normal 
untreated 
- 99.48±2.2* 98.78±1.82* 100.21±1.81* 99.21±1.9* 99.76±2.1* 99.25±2.01* 98.99±1.93* 
Diabetic 
untreated 
- 300.34±4.32 300.27±3.78 299.12±4.21 297.83±5.01 299.53±3.96 297.88±4.82 299.2±4.31 
CSLM 50 298.39±2.91 295.64±4.72 293.21±3.17 291.93±4.57 285.21±5.01 260.19±4.01* 221.43±4.51* 
CSLM 100 302.85±3.18 281.18±3.49* 269.01±3.81* 228.42±4.12* 176.14±3.49* 158.36±4.28* 134.15±3.74* 
CSLM 200 300.68±3.21 275.48±3.76* 256.31±4.1* 208.28±3.59* 156.02±2.7* 133.27±4.2* 110±3.59* 
CSRM 50 297.79±4.01 294.38±3.1 292.91±4.29* 291.11±4.18 284.49±5.34 251.11±4.36* 209.2±3.9* 
CSRM 100 296.94±3.71 278.48±4.15* 264.61±3.92* 219.13±3.61* 163.74±3.82* 148.71±3.96* 126.9±4.26* 
CSRM 200 302.71±3.58 272.62±3.36* 244.19±4.5* 201.37±3.76* 146.19±3.12* 125.31±4.27* 100.3±4.19* 
Glibenclamide 5 301.23±3.72 267.51±4.31* 228.82±4.21* 189.05±3.91* 132.7±3.56* 108.35±2.73* 91.39±3.08* 
Values are expressed as mean ± SEM (n = 6); * p < 0.05 versus diabetic untreated control group 
 




Blood glucose level (mg/dL) 
1 h 2 h 4 h 
Normal untreated - 148.15±4.28 122.59±3.6 103.71±2.9 
Diabetic untreated - 451.29±5.34 370.56±4.67 310.6±4.43 
CSLM 50 254.89±2.9* 236.13±3.24* 218.48±3.1* 
CSLM 100 176.55±3.09* 134.32±3.04* 103.71±2.93* 
CSLM 200 153.8±3.38* 120.16±3.41* 94.61±2.63* 
CSRM 50 240.78±4.83* 358.01±4.25* 288.51±3.89* 
CSRM 100 167.53±3.7* 135.19±5.39* 99.85±4.3* 
CSRM 200 139.09±2.95* 112.79±3.57* 91.37±4.17* 
Glibenclamide 5 129.58±1.98* 103.67±3.62* 84.78±2.75* 
Values are expressed as mean ± SEM (n = 6);* p < 0.05 versus the normal untreated control group 
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Body weight (% Change from initial 
weight) 
4 days 7days 14 days 
Normal 
untreated 
- 1.34±0.72 2.43±0.82 4.12±1.09 
Diabetic 
untreated 
- -5.21±0.79 -9.31±1.29 -11.74±0.89 
CSLM 50 -5.11±0.91 -8.62±0.82 -7.81±1.19* 
CSLM 100 -4.62±1.29* -7.32±0.91* -5.81±1.93* 
CSLM 200 -4.11±0.82* -6.43±0.98* -4.49±0.71* 
CSRM 50 -5.06±1.28 -8.01±0.88* -6.94±1.57* 
CSRM 100 -4.35±0.44* -7.03±1.46* -5.29±0.71* 
CSRM 200 -3.89±0.68* -6.29±1.51* -4.17±1.53* 
Glibenclamide 5 -3.78±0.81* -5.72±0.68* -3.19±0.79* 
Values are expressed as mean ± S.E.M (n = 6); * p < 0.05 versus normal untreated control group 
 
These results show that CSRM (100 and 200 
mg/kg) and CSLM at 200 mg/kg significantly 
prevented (p < 0.05) the reduction in body weight 
after the 4th day onwards, whereas CSRM at 50 
mg/kg was only able to significantly inhibit (p < 
0.05) the body weight loss only after the 7th day. 
The CSLM (50 mg/kg) significantly inhibited (p < 





In order to determine the anti-diabetic effects of 
the methanol extracts of leaves and roots of C. 
sophera; hypoglycemic effects on normal rats, 
anti-diabetic activity in alloxan-induced diabetic 
rats and anti-hyperglycemic actions both in 
normal and alloxan-induced diabetic rats 
following oral glucose challenge were evaluated. 
The effects of methanol extracts of leaves and 
roots of C. sophera on weight loss in diabetic rats 
were also assessed. 
 
The results of OGTT in normal rats could be 
correlated with the ability of the extracts to 
probably enhance the secretion of insulin in the 
likely manner of sulfonylureas and inhibit α-
glucosidases present in the border brush of small 
intestine [1 & 10]. Enhanced tissue uptake of 
blood glucose induced by C. sophera might also 
be taken into consideration as an alternate 
possibility. Furthermore, both the extracts 
exerted prominent glucose lowering effect when 
compared to normal untreated rats which leads 
to the possibility of an increased peripheral 
glucose consumption owing to insulin like effect, 
delayed insulin catabolism and reduced/inhibited 
glucose reabsorption by the kidneys [3-5]. 
 
Alloxan destroys β-cells of pancreatic islets of 
Langerhans which results in reduced insulin 
secretion thereby inducing hyperglycaemia [10]. 
The alloxan-induced diabetic rats exhibited 
persistent elevation in BGL which is the typical 
sign of diabetes mellitus. Both extracts of C. 
sophera significantly decreased the BGL in 
alloxan-induced diabetic rats on single dose 
administration, which infers that both extracts are 
effective. In alloxan-induced diabetic rats, 
impaired glucose tolerance is achieved because 
of lack of insulin which is attained by destructing 
the β-cells of pancreatic islets of Langerhans 
ultimately leading to type I diabetes [11]. 
 
The study indicates that CSLM and CSRM can 
bring about improvements in glucose tolerance in 
alloxan-induced diabetic rats, which reveals that 
insulin mimetic activity or improved glucose 
utilization mechanism may be causative factors. 
The possibility of insulin secretion from β-cells or 
its release from bound form cannot be ruled out 
as responsible mechanisms of the extract in 
causing anti-hyperglycemia in alloxan-induced 
diabetic animals [12]. Increased secretion of 
insulin from β-cells of islets of Langerhans in mild 
alloxan-induced diabetic animals (some of the β-
cells still surviving) caused by sulfonylureas, is 
an established fact. 
 
Like glibenclamide which reduced BGL in mild 
hyperglycaemic animals, CSLM and CSRM 
produced normalization of BGL compared to 
diabetic untreated control group. The possible 
mechanism producing this effect may be CSLM 
and CSRM-induced release of insulin from some 
surviving β-cells [13]. This assumption is 
supported by the fact that some herbal 
preparations can stimulate β-cells regeneration 
and peripheral glucose consumption in alloxan- 
and streptozotocin-induced diabetic rats [4,14]. 
The diabetogenic action of alloxan is mediated 
through the damaging action of reactive oxygen 
species on β-cells. The medicinal plants have 
been shown to exert anti-diabetic activity due to 
antioxidant action of secondary metabolites such 
as flavonoids, isoflavonoids, coumarins, tannins, 
phenolic acids and triterpenoids [4,15]. Thus, the 
scavenging of alloxan-induced free radicals by 
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these bioactive phytoconstituents might have 
resulted in enhanced β-cells regeneration [3,15] 
ultimately leading to anti-hyperglycemic activity 
of C. sophera. 
 
Weight loss is a serious complication of diabetes 
mellitus, which occurs due to the failure of insulin 
to convert glucose into glycogen. The other 
reason is inhibition of lipolysis due to insulin 
unavailability resulting from pancreatic β-cells 
destruction. These factors lead towards animal 
weight loss due to muscle wasting and ultimately 
death. A substantial improvement in body 
weights of alloxan-induced diabetic animals 
treated with CSRM and CSLM over the whole 
span of the study was observed.  
 
Weight loss reduction could be due to improved 
transportation of glucose into peripheral tissue 
because of decreased insulin resistance, 
enhanced lipid and protein metabolism [15]. 
These could be the implications of direct effects 
of C. sophera components on glucose 
transportation, lipolysis and protein metabolism. 
The results of blood glucose level, oral glucose 
tolerance and body weight were in good 
correlation with each other and indicated the 
beneficial effects of C. sophera on alloxan-




The findings of this study indicate that C. 
sophera extract possesses antidiabetic activity. 
This lends some support for the traditional use of 
this herb in the management of diabetes. 
However, further studies are required to 
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